This contrasts sharply with HCC, where an immune-heterogeneous TME characterized by elevated Th2, Treg, Th1, and macrophage infiltration, along with diminished B cell signatures, positions DNMT3A as an adverse prognostic factor. This evidence concerns the gene DNMT3A and hepatocellular carcinoma.